Who are Glycopyrronium/Formoterol Fumarate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tiotropium & olodaterol, UMEC/VI, GSK573719/VI 62.5/25, GSK 573719 +GW642444 125/25.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/glycopyrronium-formoterol-fumarate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Glycopyrronium/Formoterol Fumarate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Glycopyrronium/Formoterol Fumarate (Glycopyrronium/Formoterol Fumarate) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: LAMA/LABA combination (Long-Acting Muscarinic Antagonist / Long-Acting Beta-2 Agonist). Area: Respiratory / Pulmonology.

phase 3 LAMA/LABA combination (Long-Acting Muscarinic Antagonist / Long-Acting Beta-2 Agonist) Muscarinic M3 receptor; Beta-2 adrenergic receptor Respiratory / Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Glycopyrronium/Formoterol Fumarate (Glycopyrronium/Formoterol Fumarate) — AstraZeneca. Glycopyrronium is an anticholinergic agent that blocks muscarinic receptors to reduce airway secretions and improve bronchial tone, while formoterol is a long-acting beta-2 agonist that relaxes airway smooth muscle to improve airflow.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Glycopyrronium/Formoterol Fumarate TARGET	Glycopyrronium/Formoterol Fumarate	AstraZeneca	phase 3	LAMA/LABA combination (Long-Acting Muscarinic Antagonist / Long-Acting Beta-2 Agonist)	Muscarinic M3 receptor; Beta-2 adrenergic receptor
Tiotropium & olodaterol	Tiotropium & olodaterol	University of Dundee	marketed	Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA)	Muscarinic M3 receptor; beta-2 adrenergic receptor
UMEC/VI	UMEC/VI	GlaxoSmithKline	marketed	Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA)	Muscarinic M3 receptor; beta-2 adrenergic receptor
GSK573719/VI 62.5/25	GSK573719/VI 62.5/25	GlaxoSmithKline	phase 3	Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA)	Muscarinic M3 receptor; beta-2 adrenergic receptor
GSK 573719 +GW642444 125/25	GSK 573719 +GW642444 125/25	GlaxoSmithKline	phase 3	Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA)	Muscarinic M3 receptor; Beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (LAMA/LABA combination (Long-Acting Muscarinic Antagonist / Long-Acting Beta-2 Agonist) class)

AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Glycopyrronium/Formoterol Fumarate — Competitive Intelligence Brief. https://druglandscape.com/ci/glycopyrronium-formoterol-fumarate. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab